Abstract | OBJECTIVES: STUDY DESIGN: The study was a randomized, controlled clinical trial. Twenty-four white women, aged 14 to 28 years, with hypothalamic amenorrhea or oligomenorrhea were prospectively enrolled for a 12-month intervention period. Amenorrheic subjects were randomized to receive oral contraceptives, medroxyprogesterone, or placebo. Oligomenorrheic subjects were randomized to receive medroxyprogesterone or placebo. Bone mineral was measured by dual-energy x-ray absorptiometry at baseline and at 6 and 12 months. RESULTS: In amenorrheic subjects spine and total body bone mineral measurements at 12 months were greater in the oral contraceptive group than in the medroxyprogesterone and placebo groups when baseline bone mineral measurements, body weight, and age were controlled for (p < or = 0.05). There were no differences in hip bone mineral calcium and bone mineral density measurements at 12 months among the three groups. In oligomenorrheic subjects there was no detectable improvement in bone mineral associated with medroxyprogesterone use. CONCLUSIONS:
|
Authors | A C Hergenroeder, E O Smith, R Shypailo, L A Jones, W J Klish, K Ellis |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 176
Issue 5
Pg. 1017-25
(May 1997)
ISSN: 0002-9378 [Print] United States |
PMID | 9166162
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Contraceptives, Oral
- Placebos
- Medroxyprogesterone
|
Topics |
- Adolescent
- Adult
- Amenorrhea
(drug therapy, etiology)
- Bone Density
- Contraceptives, Oral
(therapeutic use)
- Female
- Humans
- Hypothalamic Diseases
(complications)
- Medroxyprogesterone
(therapeutic use)
- Patient Compliance
- Placebos
- Prospective Studies
- Time Factors
|